Mixed Commentary From First Day of Obesity CV Panel - Jefferies

Jefferies commented on Vivus (NASDAQ: VVUS) following the first day of the FDA advisory committee meeting to discuss CV testing standards for obesity drugs.

"We note mixed panel commentary still leaves the issue ambiguous of whether heart rate elevations with VVUS’s Qnexa constitutes a risk signal requiring pre-approval CV outcomes studies," the firm said. "The FDA's decision is difficult to call, but we continue to believe the risk of an approval delay is not being captured in VVUS shares."

The firm maintained their Underperform rating and price target of $12 on VVUS.

For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.

Shares of Vivus closed at $20.37 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Jefferies Starts Aehr Test Systems (AEHR) at Buy
• Quanta Services (PWR) PT Raised to $833 at Jefferies